EU approves AbbVie's Maviret for acute hepatitis C treatment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/14/2026

1. NVDA
2. ORCL
3. USO
4. SPY
5. SRRK
6. DFTX
7. AZN
8. CGEM
9. LYNX
10. ENB

Go back to EU approves AbbVie's Maviret for acute hepatitis C treatment
AbbVie (NYSE: ABBV) Delayed: 261.77 +4.65 (1.81%)
Previous Close $257.12    52 Week High $68.12 
Open $261.67    52 Week Low $50.71 
Day High $264.65    P/E 56.78 
Day Low $260.10    EPS $4.61 
Volume 4,512,417